Effect of kefir on the side effects of colon cancer chemotherapy

Evaluation of Kefir's Effects on Chemotherapy Complications in Colon Cancer Patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230107057070N1

Enrollment

Registered

2023-06-21

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon cancer. Malignant neoplasm of colon

Interventions

Intervention 1: Intervention group: 20 patients with colon cancer in stages 3 and/or 4 who received injectable treatment with FOLFOX (Folinic acid, Fluorouracil, and Oxaliplatin) in 12-session chemoth

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with stages 3 and/or 4 colon cancer treated with injectable FOLFOX chemotherapy for 12 sessions

Exclusion criteria

Exclusion criteria: Consumption of probiotic, prebiotic, or synbiotic products in the last three months Alcohol consumption Patients incapable of completing the study period Lactose malabsorption

Design outcomes

Primary

Measure	Time frame
Diarrhea. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Constipation. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Xerostomia. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Sleep disorders. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Nausea. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Weight loss. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Anorexia. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Flatulence. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Dysgeusia. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.	—

Measure

Time frame

Diarrhea. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Constipation. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Xerostomia. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Sleep disorders. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Nausea. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Weight loss. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Anorexia. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Flatulence. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.;Dysgeusia. Timepoint: At the beginning and end of the intervention. Method of measurement: Completing the questionnaire and being evaluated in person and by phone.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahareh Lashtoo Aghaee

Mazandaran University of Medical Sciences

b.aghaee@hotmail.com+98 11 5509 1125

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026